Back

Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering and cardiovascular outcomes Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Mathijs De Kleer

Academic Medical Centre, Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry
Professor P. Perrone-Filardi (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Doctor K. Mahajan (Mandi, IN)
Abstract Slides Video
Presentation thumbnail
EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia
Doctor B. Jiang (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Statin therapy and 1-year mortality in non-ischaemic acute myocardial injury: a dual-cohort study
Doctor T. Yang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Effect of apolipoprotein B reduction on major adverse cardiovascular events in randomized controlled trials of triglyceride-lowering therapies: systematic review and exploratory meta-regression
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomised trials
29 August 2025
thumbnail
Congress Presentation
Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT Legacy
28 August 2026
thumbnail
Congress Presentation
Dose-related effects of olezarsen in hypertriglyceridaemia: a systematic review and meta-analysis of 2,610 patients
29 August 2026
thumbnail
Congress Presentation
Real-world efficacy of bempedoic acid: early insights from the BEMPENET Italian Registry
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources